Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.
1. A method for treating, preventing, or delaying onset of a condition selected from ocular pemphigoid and contact lens induced neovascularization, the method comprising administering to an eye of a subject an effective amount of a compound selected from the group consisting of axitinib, cediranib, linifanib, motesanib, nintedanib, pazopanib, regorafenib, sunitinib, and tivozanib, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is administered in the form of topical ocular formulation or ocular implant.
3. The method of claim 2 , wherein the ocular implant is in the form of a semi-solid or solid sustained-release implant.
4. The method of claim 3 , wherein the ocular implant is injected into the eye of the subject.
5. The method of claim 2 , wherein the topical ocular formulation is a topical eye drop.
6. The method of claim 2 , wherein the topical ocular formulation is a solution, suspension, cream, ointment, gel, gel-forming liquid, suspension containing liposomes or micelles, spray formulation, or emulsion.
7. The method of claim 1 , wherein the compound is axitinib.
8. The method of claim 1 , further comprising administering to the eye of the subject an effective amount of an antimetabolite.
9. The method of claim 8 , wherein the antimetabolite is selected from the group consisting of mycophenolate mofetil, methotrexate, mitomycin C, 5-fluorouracil, azathioprine, and thiotepa.
10. The method of claim 8 , wherein the antimetabolite is 5-fluorouracil.
11. The method of claim 1 , wherein the condition is ocular pemphigoid.
12. The method of claim 1 , wherein the condition is contact lens induced neovascularization.
13. A method for treating or delaying onset of alkali burns, the method comprising administering to an eye of a subject an effective amount of a compound selected from the group consisting of axitinib, cediranib, linifanib, motesanib, nintedanib, pazopanib, regorafenib, sunitinib, and tivozanib, or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , wherein the compound is administered in the form of topical ocular formulation or ocular implant.
15. The method of claim 14 , wherein the ocular implant is in the form of a semi-solid or solid sustained-release implant.
16. The method of claim 15 , wherein the ocular implant is injected into the eye of the subject.
17. The method of claim 14 , wherein the topical ocular formulation is a topical eye drop.
18. The method of claim 14 , wherein the topical ocular formulation is a solution, suspension, cream, ointment, gel, gel-forming liquid, suspension containing liposomes or micelles, spray formulation, or emulsion.
19. The method of claim 13 , wherein the compound is axitinib.
20. The method of claim 13 , further comprising administering to the eye of the subject an effective amount of an antimetabolite.
21. The method of claim 20 , wherein the antimetabolite is selected from the group consisting of mycophenolate mofetil, methotrexate, mitomycin C, 5-fluorouracil, azathioprine, and thiotepa.
22. The method of claim 20 , wherein the antimetabolite is 5-fluorouracil.